Published in Heart Rhythm on August 22, 2010
2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol (2012) 2.08
Effects of regional mitochondrial depolarization on electrical propagation: implications for arrhythmogenesis. Circ Arrhythm Electrophysiol (2014) 0.85
Early Repolarization Syndrome; Mechanistic Theories and Clinical Correlates. Front Physiol (2016) 0.75
Sudden cardiac arrest associated with early repolarization. N Engl J Med (2008) 8.26
Cellular basis for the electrocardiographic J wave. Circulation (1996) 5.25
Long-term outcome associated with early repolarization on electrocardiography. N Engl J Med (2009) 4.53
J wave syndromes. Heart Rhythm (2009) 3.54
J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol (2008) 2.87
Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle, and heart. J Biol Chem (1995) 2.62
Brugada syndrome. Pacing Clin Electrophysiol (2006) 2.61
Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. J Electrocardiol (2000) 2.54
Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat Med (2002) 2.45
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation (1997) 2.32
Spontaneous episode of polymorphic ventricular tachycardia in a patient with intermittent Brugada syndrome. J Cardiovasc Electrophysiol (2001) 2.25
Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc Electrophysiol (2009) 2.20
Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol (1998) 2.19
The normal RS-T segment elevation variant. Am J Cardiol (1961) 2.16
Ventricular fibrillation in a patient with prominent J (Osborn) waves and ST segment elevation in the inferior electrocardiographic leads: a Brugada syndrome variant? J Cardiovasc Electrophysiol (2000) 2.03
Does the "pacemaker current" generate the diastolic depolarization in the rabbit SA node cells? Pflugers Arch (1983) 2.01
I(to) and action potential notch are smaller in left vs. right canine ventricular epicardium. Am J Physiol (1996) 1.91
Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm (2010) 1.89
N-terminal transmembrane domain of the SUR controls trafficking and gating of Kir6 channel subunits. EMBO J (2003) 1.68
ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am J Physiol (1998) 1.68
Immunolocalization of KATP channel subunits in mouse and rat cardiac myocytes and the coronary vasculature. BMC Physiol (2005) 1.53
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Early repolarization on scalar electrocardiogram. Am J Med Sci (1995) 1.33
Sulfonylurea receptors: ABC transporters that regulate ATP-sensitive K(+) channels. Biochim Biophys Acta (1999) 1.18
Cardiac sarcolemmal K(ATP) channels: Latest twists in a questing tale! J Mol Cell Cardiol (2009) 1.17
Characterization of J wave in a patient with idiopathic ventricular fibrillation. Heart Rhythm (2006) 1.15
Expression of ATP-sensitive K+ channel subunits during perinatal maturation in the mouse heart. Pediatr Res (2005) 1.14
ST-segment elevation in the early repolarization syndrome, idiopathic ventricular fibrillation, and the Brugada syndrome: cellular and clinical linkage. J Electrocardiol (2005) 1.10
Brugada syndrome with atypical ECG: downsloping ST-segment elevation in inferior leads. J Electrocardiol (2004) 1.07
Role of ATP-sensitive K+ channel on ECG ST segment elevation during a bout of myocardial ischemia. A study on epicardial mapping in dogs. Circulation (1993) 1.07
Coassembly of different sulfonylurea receptor subtypes extends the phenotypic diversity of ATP-sensitive potassium (KATP) channels. Mol Pharmacol (2008) 0.99
Molecular assembly and subcellular distribution of ATP-sensitive potassium channel proteins in rat hearts. FEBS Lett (2003) 0.98
The properties of the Kir6.1-6.2 tandem channel co-expressed with SUR2A. Pflugers Arch (2000) 0.96
Identification of two types of ATP-sensitive K+ channels in rat ventricular myocytes. Life Sci (2006) 0.94
Different responses of epicardium and endocardium to KATP channel modulators during regional ischemia. Am J Physiol (1996) 0.93
Genomic organization and expression of KCNJ8/Kir6.1, a gene encoding a subunit of an ATP-sensitive potassium channel. Gene (1998) 0.90
Random assembly of SUR subunits in K(ATP) channel complexes. Channels (Austin) (2008) 0.90
KATP channel: relation with cell metabolism and role in the cardiovascular system. Int J Biochem Cell Biol (2005) 0.89
Ventricular fibrillation in a patient with prominent j wave in the inferior and lateral electrocardiographic leads after gastrostomy. Pacing Clin Electrophysiol (2006) 0.89
Brugada syndrome characterized by the appearance of J waves. Pacing Clin Electrophysiol (2000) 0.87
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 1.86
Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res (2004) 1.85
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol (2006) 1.78
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm (2006) 1.74
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation (2011) 1.60
A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol (2010) 1.60
Early repolarization syndrome: a decade of progress. J Electrocardiol (2013) 1.59
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol (2004) 1.53
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm (2006) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm (2011) 1.46
Resolving the M-cell debate: why and how. Heart Rhythm (2011) 1.45
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm (2008) 1.42
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J (2011) 1.37
Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol (2004) 1.35
Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol (2007) 1.32
Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol (2003) 1.31
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf (2008) 1.30
Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol (2007) 1.28
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm (2008) 1.27
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One (2012) 1.23
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
The role of local voltage potentials in outflow tract ectopy. Europace (2010) 1.20
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
M cells in the human heart. Circ Res (2010) 1.17
Dimethyl lithospermate B, an extract of Danshen, suppresses arrhythmogenesis associated with the Brugada syndrome. Circulation (2006) 1.16
Potential proarrhythmic effects of biventricular pacing. J Am Coll Cardiol (2005) 1.15
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Value of electrocardiographic parameters and ajmaline test in the diagnosis of Brugada syndrome caused by SCN5A mutations. Circulation (2004) 1.14
Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol (2009) 1.13
Atrial-selective sodium channel block for the treatment of atrial fibrillation. Expert Opin Emerg Drugs (2009) 1.12
Accelerated inactivation of the L-type calcium current due to a mutation in CACNB2b underlies Brugada syndrome. J Mol Cell Cardiol (2009) 1.11
Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome. Am J Med Genet A (2011) 1.11
Short QT syndrome. Genotype-phenotype correlations. J Electrocardiol (2005) 1.11
Prominent I(Ks) in epicardium and endocardium contributes to development of transmural dispersion of repolarization but protects against development of early afterdepolarizations. J Cardiovasc Electrophysiol (2002) 1.10
HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol (2003) 1.09
Pharmacological approach to the treatment of long and short QT syndromes. Pharmacol Ther (2008) 1.09